Hèctor Corominas

Professor titular / Professor Tenure track position

Universitat Autònoma de Barcelona (UAB)
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Objective The objective of this study was to assess the risk of cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs). Methods We analysed the 2000–2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated with b/tsDMARDs. Patients with a history of cancer were excluded. Incidence rates (IRs) were analysed, and adjusted Cox regression models were used to estimate hazard ratios (HRs) for all cancers excluding non-melanoma skin cancer (NMSC), as well as for NMSC. Treatment with a TNF inhibitor (TNFi) served as the reference for comparison. Results Among 4635 of the BIOBADASER III registry patients with RA (mean age 55.5 years; 79% female; median follow-up 3.6 years), 187 incident cancers were identified. For all cancers excluding NMSC, the adjusted HRs (95% CI) compared with TNFi were: 1.2 (0.8–1.6) for IL6i, 0.9 (0.5–1.4) for CD20i, 1.2 (0.8–1.8) for JAKi and 1.1 (0.8–1.6) for CTLA4-A. For NMSC, the adjusted HRs (95% CI) were 0.6 (0.2–1.5) for IL6i, 0.6 (0.2–1.8) for CD20i, 0.7 (0.2–2) for JAKi, and 1.1 (0.5–2.6) for CTLA4-A. No increased cancer risk was observed when adjusting for cardiovascular risk or treatment line, for either cancer type. Conclusion In this large, real-world cohort of RA patients, we found no increased cancer risk associated with any bDMARDs or tsDMARDs compared with TNFi.

Year:

2026

Year:

2026

Background and Objectives: IgG4-related disease is a chronic fibro-inflammatory condition. Despite the development of classification and responder indexes, reliable biomarkers for disease activity and therapeutic monitoring remain limited. We evaluate the performance of a panel of biomarkers, including cytokine profiles, plasmablasts and conventional markers. Materials and Methods: We conducted a cross-sectional, single-center study, involving 35 patients diagnosed with IgG4-RD. Disease activity was evaluated using the IgG4-RD Responder Index (RI), Damage Index (DI) and clinical assessment. Laboratory evaluation included serum IgG4, total IgG, CRP, ESR, eosinophils, IgE, complement levels, and cytokine profiling via multiplex immunoassay. B cell subpopulations were analyzed by flow cytometry. Statistical analyses were performed using STATA/BE 17.0. Results: Patients with active disease (RI > 4 or clinical judgment) exhibited significantly higher levels of total IgG (p = 0.02), IgG4 (p = 0.01), and IL-5 (p = 0.03). PET-positive patients showed a Th1-skewed immune profile, with elevated IFN-γ/IL-4 (p < 0.001), reduced IL-21/IFN-γ (p = 0.03), and increased eosinophils (p = 0.03). Clinician-assessed active disease was associated with higher total IgG levels (p = 0.01). Treatment-specific effects were observed: prednisone was associated with lower IgG4 and C3 levels. Notably, plasmablasts did not consistently correlate with clinical or imaging activity scores, possibly reflecting treatment status or B cell dynamics. Conclusions: This study demonstrates that cytokine ratios, particularly those involving IL-5, IL-13, IL-21, and IFN-γ, offer complementary information to traditional serological markers for IgG4-RD activity. While PET/CT-defined activity was best reflected by biomarkers of an IFN-γ-mediated pathway, the IgG4-RD RI demonstrated a stronger association with conventional humoral markers like serum IgG4 and total IgG. None of these biomarkers correlated with organ damage.

Year:

2026

Objectives To assess the impact of chronic inflammatory burden on the risk of aortic valve outcomes and atrioventricular block (AVB) in SpA. Methods Ambispective cohort study of 461 SpA patients meeting ASAS criteria between September 2022 and April 2024. Chronic inflammation burden was measured by symptom duration, number of DMARDs discontinued due to inefficacy and total exposure to persistent inflammation. Statistical analysis was performed with multiple time-dependent Cox regression, maintaining a variable-to-event ratio. Results Disease duration, especially from initial musculoskeletal (MSK) symptoms, affected all outcomes. Every five-year increase in symptom duration raised the risk of aortic regurgitation (HR 1.21, 95% CI 1.06–1.37), valve sclerosis (HR 1.07, 95% CI 1.02–1.12), root dilation (HR 1.31, 95% CI 1.08–1.59) and AVB (HR 1.34, 95% CI 1.05–1.71). Age also increased risks, particularly for aortic regurgitation (HR 1.46 per decade) and valve sclerosis (HR 1.74 per decade). Surprisingly, hypertension showed a consistent protective effect, decreasing the risk for aortic root dilation (HR 0.55, 95% CI 0.36–0.84), valve sclerosis (HR 0.62, 95% CI 0.40–0.96) and aortic regurgitation (HR 0.60, 95% CI 0.37–0.98). Peripheral SpA significantly predicted aortic valve sclerosis (HR 1.95, 95% CI 1.13–3.36), and enthesitis strongly influenced AVB risk (HR 3.04, 95% CI 1.24–7.44). Conclusions The duration of MSK symptoms more strongly predicted all outcomes than extra-MSK symptoms. Age’s impact mirrored general population trends. Surprisingly, hypertension protected against aortic conditions, prompting further research into IL-17 therapies. Peripheral SpA significantly predicted aortic valve sclerosis, and enthesitis strongly predicted AVB.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Objective To investigate the prevalence, timing and risk factors at diagnosis associated with relapses in giant cell arteritis (GCA), with a separate analysis of major and minor relapses. Methods A retrospective review of patients from the Spanish multicentre GCA registry (ARTESER) was conducted. Relapses were classified using 2018 EULAR definitions. Results We included 1284 patients with at least one year of follow-up. Twenty-six percent experienced relapses, with cumulative rates of 18.1%, 27.9%, 37.6% and 44.8% at 1, 2, 3 and 4 years, respectively. Multiple relapses were observed in 14.6% of patients during the first year, 10.5% in the second, 9% in the third and 17.8% in the fourth, reflecting the relapsing-remitting nature of GCA. According to EULAR definitions, major relapses represented 26.7% of all recorded relapses and affected 7.6% of patients. Younger age at diagnosis (HR: 0.976, P = 0.004) and a higher total dose of prednisone at the first relapse (HR: 0.998, P = 0.003) were associated with a reduced risk of overall relapses. Severe ischemic complications (HR: 4.126, P < 0.001) and large-vessel (LV) involvement at diagnosis (HR: 1.992, P = 0.024) significantly increased the risk of major relapses, while younger age (HR: 0.970, P = 0.002) was protective against minor relapses. Conclusions Major relapses are not so uncommon, representing a quarter of all relapses. The presence of severe ischemic complications and LV involvement at diagnosis substantially increase their risk.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (17)

Isabel Haro

Research Scientist

Consejo Superior de Investigaciones Cientificas

SPAIN
View details

Joan Calvet

Institute of Research and Innovation Parc Tauli

SPAIN
View details

Laura Martinez-Martinez

Head of Department

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Diaz-Torne Cesar

Associate Professor

Universitat Autònoma de Barcelona Facultat de Medicina

SPAIN
View details

María José Gómara

Tenured Scientist

Consejo Superior de Investigaciones Cientificas

SPAIN
View details

José Ríos

Lecturer Professor & Reseacher

Universitat Autònoma de Barcelona (UAB)

SPAIN
View details

Silvia Vidal

Associate professor

University of Barcelona

SPAIN
View details

Paloma Vela Casasempere

Instituto de Investigación Sanitaria y Biomédica de Alicante

SPAIN
View details

Anna López-Ferrer

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Javier de Toro

Catedrático de Escuela Universitaria

Universidade da Coruña

SPAIN
View details

Cristina Campos Fernández

Head of the Rheumatology Department.

Generalitat Valenciana

SPAIN
View details

Javier Narvaez

Chief of Deparment

University of Barcelona

SPAIN
View details

Eugenio De Miguel

MD, PhD, Prof

La Paz University Hospital

SPAIN
View details

Dacia Cerdà Gabaroi

Associate Professor

University of Barcelona

SPAIN
View details

Cristina Macía-Villa

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

SPAIN
View details

Sara Manrique-Arija

Associate Lecturer

Universidad de Málaga Facultad de Medicina

SPAIN
View details

Lucía Otero Varela

Lecturer

Universidad CEU San Pablo

SPAIN
View details